open access

Vol 13, No 1 (2008)
Untitled
Published online: 2008-01-01
Submitted: 2007-07-09
Get Citation

Tumour surface area as a prognostic factor in primary and recurrent glioblastoma irradiated with Ir implantation

Andrzej Lebioda, Agnieszka Żyromska, Roman Makarewicz, Jacek Furtak
DOI: 10.1016/S1507-1367(10)60077-6
·
Rep Pract Oncol Radiother 2008;13(1):15-22.

open access

Vol 13, No 1 (2008)
Untitled
Published online: 2008-01-01
Submitted: 2007-07-09

Abstract

Background

To evaluate the impact of tumour surface area (TSA) on survival of patients treated with 192Ir implantation for glioblastoma multiforme (GBM).

Methods/Materials

The analysis of survival and prognostic factors was performed based on a retrospective study group of 120 patients (74 males and 46 females; mean age 53 years; mean KPS score 74.6) irradiated with 192Ir for GBM between 1999 and 2003. There were 72 (60%) patients with recurrent and 48 (40%) with primary inoperable tumour. Patients with recurrences were initially treated with surgery and external beam radiotherapy (EBRT; mean total dose (MTD) 53.5Gy). Individuals with primary inoperable glioblastoma underwent EBRT (MTD 37.2Gy) after brachytherapy completion. All patients were irradiated with 192Ir with a total dose of 15Gy given in 5 fractions.

Results

For the total group of patients 1-year and 2-year survival were 22% and 11%, respectively, with a median survival time (MST) of 6.1 months. The multivariate Cox analysis of the best fit (Chi2=22.98, p=0.000041) distinguished such variables as: patient age (p=0.002), performance status (p=0.04) and tumour surface area (p=0.04) to significantly affect survival. Patients with TSA<90 cm2 had better prognosis compared to those with TSA≥90cm2 (p<0.001).

Conclusions

Tumour surface area is an independent prognostic factor in patients irradiated with 192Ir for glioblastoma multiforme. TSA less than 90cm2 predicts significantly longer survival and appears to be a more powerful prognostic variable than tumour volume.

Abstract

Background

To evaluate the impact of tumour surface area (TSA) on survival of patients treated with 192Ir implantation for glioblastoma multiforme (GBM).

Methods/Materials

The analysis of survival and prognostic factors was performed based on a retrospective study group of 120 patients (74 males and 46 females; mean age 53 years; mean KPS score 74.6) irradiated with 192Ir for GBM between 1999 and 2003. There were 72 (60%) patients with recurrent and 48 (40%) with primary inoperable tumour. Patients with recurrences were initially treated with surgery and external beam radiotherapy (EBRT; mean total dose (MTD) 53.5Gy). Individuals with primary inoperable glioblastoma underwent EBRT (MTD 37.2Gy) after brachytherapy completion. All patients were irradiated with 192Ir with a total dose of 15Gy given in 5 fractions.

Results

For the total group of patients 1-year and 2-year survival were 22% and 11%, respectively, with a median survival time (MST) of 6.1 months. The multivariate Cox analysis of the best fit (Chi2=22.98, p=0.000041) distinguished such variables as: patient age (p=0.002), performance status (p=0.04) and tumour surface area (p=0.04) to significantly affect survival. Patients with TSA<90 cm2 had better prognosis compared to those with TSA≥90cm2 (p<0.001).

Conclusions

Tumour surface area is an independent prognostic factor in patients irradiated with 192Ir for glioblastoma multiforme. TSA less than 90cm2 predicts significantly longer survival and appears to be a more powerful prognostic variable than tumour volume.

Get Citation

Keywords

glioblastoma; tumor surface area; tumor volume; prognostic factors

About this article
Title

Tumour surface area as a prognostic factor in primary and recurrent glioblastoma irradiated with Ir implantation

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 13, No 1 (2008)

Pages

15-22

Published online

2008-01-01

DOI

10.1016/S1507-1367(10)60077-6

Bibliographic record

Rep Pract Oncol Radiother 2008;13(1):15-22.

Keywords

glioblastoma
tumor surface area
tumor volume
prognostic factors

Authors

Andrzej Lebioda
Agnieszka Żyromska
Roman Makarewicz
Jacek Furtak

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl